RxDoctor Payments Data

June Argel

Nurse Practitioner · Warren, MINPI 1871037903

Payments from drug & device makers

$3,630in general payments, 2019–2025

Across 65 payments — averaging $55.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • Acadia Pharmaceuticals Inc$352
  • AstraZeneca$272
  • Otsuka America Pharmaceutical, Inc.$250
  • Sun Pharmaceutical Industries Inc.$249
  • Boehringer Ingelheim$125
  • plus $400 from 4 others

What the payments were for

  • Food & beverage$3,627100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,630 in reported general payments places this provider in the 90th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$173,175
Medicare patients
273
Services billed
2,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate26$212,116
BiktarvyBictegrav/Emtricit/Tenofov Ala18$76,057
OtezlaApremilast11$56,923
EliquisApixaban148$36,763
TrulicityDulaglutide29$33,579
GemtesaVibegron134$32,413
XareltoRivaroxaban72$20,730
NuedextaDextromethorphan Hbr/Quinidine25$18,818
Risperdal ConstaRisperidone Microspheres15$16,078
Breo ElliptaFluticasone/Vilanterol32$14,010
JardianceEmpagliflozin41$13,778
Novofine AutocoverPen Needle, Diabetic, Safety111$10,052
Ondansetron OdtOndansetron73$9,585
Atorvastatin Calcium467$8,242
MyrbetriqMirabegron34$8,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,982$212,11626 claims
Avanir Pharmaceuticals, Inc.Nuedexta$110$18,81825 claims
Boehringer IngelheimJardiance$125$13,77841 claims
AstraZenecaFarxiga, Symbicort$272$9,36640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →